| Christopher Vincent Lisi, MD | |
|
2800 Marcus Ave, New Hyde Park, NY 11042-1113 | |
| (516) 622-3387 | |
| Not Available |
| Full Name | Christopher Vincent Lisi |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 12 Years |
| Location | 2800 Marcus Ave, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861767055 | NPI | - | NPPES |
| 291328 | Other | NY | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 291328 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Richmond University Medical Center | Staten island, NY | Hospital |
| Staten Island University Hospital | Staten island, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Amboy Medical Practice Pc | 2860538170 | 129 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.
Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.
Uri Laserson, PhD, Assistant Professor in the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai, and collaborators have been awarded one of 85 grants announced today from the Chan Zuckerberg Initiative DAF (CZI), an advised fund of Silicon Valley Community Foundation.
Demand swells and attendance soars for the most accurate and up-to-date information about the constantly changing pharmaceutical industry, especially pharma competitive intelligence. Even in a challenging economic environment, the Pharma CI Conference continues to expand because industry leaders understand that they must face the future together, and the Pharma CI Conference is the one place that can happen.
› Verified 4 days ago
| Entity Name | Prohealth Care Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275596280 PECOS PAC ID: 4486544186 Enrollment ID: O20040317000468 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.
Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.
Uri Laserson, PhD, Assistant Professor in the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai, and collaborators have been awarded one of 85 grants announced today from the Chan Zuckerberg Initiative DAF (CZI), an advised fund of Silicon Valley Community Foundation.
Demand swells and attendance soars for the most accurate and up-to-date information about the constantly changing pharmaceutical industry, especially pharma competitive intelligence. Even in a challenging economic environment, the Pharma CI Conference continues to expand because industry leaders understand that they must face the future together, and the Pharma CI Conference is the one place that can happen.
› Verified 4 days ago
| Entity Name | Amboy Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700037975 PECOS PAC ID: 2860538170 Enrollment ID: O20090930000024 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.
Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.
Uri Laserson, PhD, Assistant Professor in the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai, and collaborators have been awarded one of 85 grants announced today from the Chan Zuckerberg Initiative DAF (CZI), an advised fund of Silicon Valley Community Foundation.
Demand swells and attendance soars for the most accurate and up-to-date information about the constantly changing pharmaceutical industry, especially pharma competitive intelligence. Even in a challenging economic environment, the Pharma CI Conference continues to expand because industry leaders understand that they must face the future together, and the Pharma CI Conference is the one place that can happen.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Vincent Lisi, MD 2800 Marcus Ave, New Hyde Park, NY 11042-1113 Ph: (516) 622-6000 | Christopher Vincent Lisi, MD 2800 Marcus Ave, New Hyde Park, NY 11042-1113 Ph: (516) 622-3387 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.
Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.
Uri Laserson, PhD, Assistant Professor in the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai, and collaborators have been awarded one of 85 grants announced today from the Chan Zuckerberg Initiative DAF (CZI), an advised fund of Silicon Valley Community Foundation.
Demand swells and attendance soars for the most accurate and up-to-date information about the constantly changing pharmaceutical industry, especially pharma competitive intelligence. Even in a challenging economic environment, the Pharma CI Conference continues to expand because industry leaders understand that they must face the future together, and the Pharma CI Conference is the one place that can happen.
› Verified 4 days ago
Andrea Vambutas, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Lijmc-dept. Of Otolaryngology, 270-05 76th Avenue, New Hyde Park, NY 11040 Phone: 718-470-7955 | |
Kenneth Anthony Scioscia, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2800 Marcus Ave, New Hyde Park, NY 11042 Phone: 516-622-3377 | |
Ron Mitzner, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6 Ohio Dr Ste 202, New Hyde Park, NY 11042 Phone: 516-775-2800 Fax: 516-775-0859 | |
Dr. Joel Evan Portnoy, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6 Ohio Dr Ste 202, New Hyde Park, NY 11042 Phone: 516-775-2800 Fax: 516-775-0859 | |
Mark Shikowitz, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Lijmc-dept. Of Otolaryngology, 270-05 76th Avenue, New Hyde Park, NY 11040 Phone: 718-470-7557 | |
Dr. Moshe Ephrat, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6 Ohio Dr Ste 202, New Hyde Park, NY 11042 Phone: 516-772-2800 Fax: 516-775-0859 | |
Lucio Malaco Pereira, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 430 Lakeville Rd, New Hyde Park, NY 11042 Phone: 718-470-7550 |